Work Here?
Dyne Therapeutics
Work Here?
Develops muscle-disease therapies using FORCE platform
Dyne Therapeutics
Work Here?
Develops muscle-disease therapies using FORCE platform
Overview
Dyne Therapeutics develops therapies for serious muscle diseases using its FORCE™ platform, which helps deliver oligonucleotide medicines to muscle tissue. Through a portfolio of experimental therapies, the company advances them in clinical trials (ACHIEVE and DELIVER) with the aim of treating rare muscle diseases. The product works by enhancing targeted delivery of oligonucleotides to muscle, enabling existing genetic medicines to reach affected tissues more effectively. Dyne differentiates itself by its proprietary FORCE™ technology and its focus on rare muscle diseases, positioning itself for growth as trials progress toward potential commercialization. The company’s goal is to bring effective treatments to patients and families affected by serious muscle diseases, expanding options as its therapies advance through development and, potentially, regulatory approval.
About Dyne Therapeutics
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Headquarters
Waltham, Massachusetts
Founded
2017
People at Dyne Therapeutics
People at Dyne Therapeutics who can refer or advise you
Simplify's Take
What believers are saying
- Preclinical data shows sustained dystrophin expression and muscle function improvement after single low dose[1].
- ACHIEVE trial shows dose-dependent splicing correction and functional improvement in DM1 patients[3].
- Dyne secured $400M debt facility to support US launches of DMD and DM1 therapies within two years[3]
What critics are saying
- Sarepta's upadacersen dominates DMD market with 80% adoption, blocking Dyne's switch opportunities in 12–18 months
- FDA rejection risk for accelerated approval due to inadequate Phase 1/2 data persists in 6–12 months
- Dyne faces insolvency within 12 months if FDA denies approval due to $200M debt and equity dilution
What makes Dyne Therapeutics unique
- Dyne's FORCE™ platform targets TfR-1 for precise oligonucleotide delivery to muscle and CNS[1][2].
- Dyne pioneers low-dose, infrequent therapy for DM1 using FORCE™ platform validation[4][6].
- Dyne advances clinical programs for DMD and DM1 with fast track and orphan drug designations[3].
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$1.8B
Above
Industry Average
Funded Over
9 Rounds
Stock Price
Growth & Insights and Company News
6 month growth
↓ -3%1 year growth
↑ 0%2 year growth
↓ -2%(Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an upsized underwritten public offering of 18,980,478 shares of its common stock at a public offering price of $18.44 per share.
Dyne Therapeutics is Hiring for 63 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Dyne Therapeutics
Industries
Biotechnology
Healthcare
Company Size
201-500
Company Stage
IPO
Headquarters
Waltham, Massachusetts
Founded
2017
Dyne Therapeutics is Hiring for 63 Jobs on Simplify!
Find jobs on Simplify and start your career today